The stock of Alliqua Biomedical DE (NASDAQ:ALQA) registered a decrease of 0.49% in short interest. ALQA’s total short interest was 363,200 shares in September as published by FINRA. Its down 0.49% from 365,000 shares, reported previously. With 50,800 shares average volume, it will take short sellers 7 days to cover their ALQA’s short positions. The short interest to Alliqua Biomedical DE’s float is 1.75%. The stock decreased 2.79% or $0.026 on September 13, hitting $0.912. About 10,987 shares traded hands. Alliqua Biomedical Inc (NASDAQ:ALQA) has declined 35.17% since February 8, 2016 and is downtrending. It has underperformed by 51.66% the S&P500.
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The company has a market cap of $27.00 million. The Company’s businesses include advanced wound care and contract manufacturing. It currently has negative earnings. The Firm operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc.
The institutional sentiment increased to 1 in 2016 Q2. Its up 0.45, from 0.55 in 2016Q1. The ratio improved, as 4 funds sold all Alliqua Biomedical Inc shares owned while 7 reduced positions. 0 funds bought stakes while 11 increased positions. They now own 8.86 million shares or 14.99% less from 10.42 million shares in 2016Q1.
Pura Vida Investments Llc holds 0.28% of its portfolio in Alliqua Biomedical Inc for 583,026 shares. Suffolk Capital Management Llc owns 1.21 million shares or 0.17% of their US portfolio. Moreover, Perceptive Advisors Llc has 0.15% invested in the company for 1.92 million shares. The New Jersey-based Sabby Management Llc has invested 0.09% in the stock. Tekla Capital Management Llc, a Massachusetts-based fund reported 1.65 million shares.
Out of 3 analysts covering Alliqua Inc (NASDAQ:ALQA), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alliqua Inc has been the topic of 7 analyst reports since September 28, 2015 according to StockzIntelligence Inc. H.C. Wainwright maintained the stock on August 10 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.